Sugi Predict

Sugi Predict / Compounds / SCHEMBL2593426

SCHEMBL2593426

SCHEMBL2593426

CS(=O)(=O)c1cc(C(=O)O)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTK2B Q14289 2/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ CDC25B P30305 1/20 0.49
▸ RAB9A P51151 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ PKM P14618 1/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ ACLY P53396 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.42
▸ FABP4 P15090 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15836200 0.85 CMA1 (0.43) PTK2BSMN1; SMN2PTGS2
SCHEMBL4597784 0.85 LMNA (0.51) PTK2BSMN1; SMN2CDC25BRAB9AHTT
SCHEMBL29499772 0.85 LMNA (0.51) PTK2BSMN1; SMN2CDC25BRAB9AHTT
SCHEMBL20084009 0.84 ACLY (0.50) PTK2BACLY
SCHEMBL31400646 0.84 ACLY (0.50) PTK2BACLY
SCHEMBL19157383 0.84 PTK2B (0.43) PTK2BSMN1; SMN2LMNAPTGS2
SCHEMBL9900899 0.84 PTK2B (0.42) PTK2BSMN1; SMN2PTGS2
SCHEMBL5405584 0.82 CDC25B (0.53) PTK2BSMN1; SMN2CDC25BHTTPKM
SCHEMBL16173484 0.82 PTK2B (0.55) PTK2BSMN1; SMN2CDC25BRAB9AHTT
SCHEMBL940353 0.81 PTK2B (0.58) PTK2BSMN1; SMN2CDC25BRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
EP-2595989-B1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2016-07-13 — — EP disclosed
EP-2595989-B1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2016-07-13 — — EP disclosed
US-9365588-B2 Benzoxazines as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 — — US disclosed
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-16 — — US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 — — US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 — — US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 — — US disclosed
US-8598164-B2 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-12-03 — — US disclosed
US-20040116709-A1 Process for producing optically active n-aryl-1-amino-2-propanol derivatives KANEKA CORPORATION (JP) 2004-06-17 — — US disclosed
EP-1367053-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES KANEKA CORPORATION (JP) 2003-12-03 — — EP disclosed
US-5670544-A ANTIISCHEMIC AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1997-09-23 — — US disclosed
EP-0589336-B1 Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents HOECHST AG (DE) 1997-01-08 — — EP disclosed
US-5591754-A Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith HOECHST AKTIENGESELLSCHAFT (DE) 1997-01-07 — — US disclosed
EP-0602522-B1 Substituted Benzoylguanidines, method for their preparation, their use as antiarrhythmic agents HOECHST AG (DE) 1996-05-29 — — EP disclosed
EP-0602522-A1 Substituted Benzoylguanidines, method for their preparation, their use as antiarrhythmic agents HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-22 — — EP disclosed
EP-0589336-A1 Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents HOECHST AKTIENGESELLSCHAFT (DE) 1994-03-30 — — EP disclosed
US-4017256-A FIBER DYEABLE WITH DISPERSE DYES AND FIBER DYEABLE WITH REACTIVE DYES CIBA-GEIGY CORPORATION (US) 1977-04-12 — — US disclosed
US-3951588-A Process for dyeing and printing or optical brightening of cellulose materials CIBA-GEIGY CORPORATION (US) 1976-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels KCNJ2, TRPV1, KCNJ1 PTK2B 2247/4885SMN1; SMN2 1198/4885CDC25B 1644/4885
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS KCNJ1, KCNJ2, KCNJ11 PTK2B 3610/4885SMN1; SMN2 975/4885CDC25B 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.